AzTrials
AzTrials

Metastatic Castration-resistant Prostate CancerPhase 1/2LuCABNCT05340374

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

A Phase 1/2 study testing Cabazitaxel and 177Lu-PSMA-617 in people with Metastatic Castration-resistant Prostate Cancer and mCRPC, run by Peter MacCallum Cancer Centre, Australia at 2 sites in Australia.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Read more about this study

Who is it for?
Ages 18 years and older, men only
What is being tested?
Cabazitaxel and 177Lu-PSMA-617
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
2 sitesAustralia
Study dates
14 Jul 2022to Dec 2026
Phase
Phase 1/2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male patients aged 18 years or older at the time of informed consent.
  • Patient has provided written informed consent.
  • Histologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell differentiation.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
  • Patients must have had prior treatment with docetaxel.
  • Patients must have progressed on a second-generation androgen receptor (AR)-targeted agent (e.g., enzalutamide, abiraterone, or apalutamide) in the castrate-resistant setting.
Show all 27Show fewer
  • Patients must have progressive disease. The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) defines this as any one of the following:
  • PSA progression: minimum of two rising PSA values from a baseline measurement with an interval of ≥ 1 week between each measurement
  • Soft tissue or visceral disease progression as per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) criteria
  • Bone progression: ≥ 2 new lesions on bone scan
  • At least three weeks since the completion of surgery prior to registration.
  • Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist).
  • Serum testosterone levels ≤ 1.75nmol/L within 28 days prior to registration.
  • Imaging evidence of metastatic disease documented with either whole body bone scan (WBBS) or computed tomography (CT) scan performed within 28 days prior to registration.
  • Significant prostate-specific membrane antigen (PSMA) avidity on PSMA PET/CT, defined as a minimum uptake of SUVmax 15 at a site of disease.
  • Patients must have a life expectancy ≥ 12 weeks.
  • Assessed by a medical oncologist as suitable for treatment with cabazitaxel and 177Lu-PSMA-617.
  • Patients must have adequate bone marrow, hepatic and renal function documented within 28 days prior to registration, defined as:
  • Haemoglobin ≥ 90 g/L independent of transfusions (no red blood cell transfusion in last 28 days prior to registration)
  • Absolute neutrophil count (ANC) ≥ 1.5x10^9/L
  • Platelets ≥ 150 x10^9/L
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome, where this applies for the unconjugated bilirubin component
  • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN if there is no evidence of liver metastasis or ≤ 5 x ULN in the presence of liver metastases
  • Albumin ≥ 25 g/L
  • Adequate renal function: patients must have a creatinine clearance estimated of ≥ 40 mL/min using the Cockcroft-Gault equation
  • Sexually active patients are willing to use medically acceptable forms of barrier contraception.
  • Willing and able to comply with all study requirements, including all treatments and the timing and nature of all required assessments.

Who cannot join

  • Superscan on WBBS or diffuse marrow disease on PSMA PET.
  • Site(s) of measurable disease that are FDG-positive with low PSMA expression (SUVmax <10).
  • Prior treatment with cabazitaxel or 177Lu-PSMA-617.
  • Contraindications to the use of corticosteroid treatment.
  • Other malignancies within the previous 2-years other than basal cell or squamous cell carcinomas of skin or other cancers that are unlikely to recur within 24 months.
  • Presence of untreated brain metastases or leptomeningeal metastases.
Show all 11Show fewer
  • Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable for ≥ four weeks.
  • Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety.
  • Persistent toxicities (CTCAE v5.0 >/= Grade 2) caused by previous cancer therapy, excluding alopecia.
  • Known HIV or hepatitis B or C infection.
  • Radiotherapy or systemic anti-cancer therapies administered within 14 days prior to registration, excluding androgen deprivation therapy (ADT).

Trial locations and contacts

2 sites in 1 country.

Australia2 sites

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000

  • St Vincent's Hospital

    Sydney, New South Wales, 2000

Other trials in Australia

About this study

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Read the detailed description

This prospective, single-centre, single-arm, open label, phase I/II trial will assess the safety, efficacy and anti-tumour activity of cabazitaxel in combination with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).

This study aims to assess and establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of cabazitaxel in combination with 177Lu-PSMA-617 in patients with mCRPC.

32-44 men with mCRPC who have progressed on prior docetaxel and a second-generation AR antagonist will be enrolled in this trial in two stages: dose escalation and a dose expansion phase over a period of 18 months.

Being tested
Cabazitaxel, 177Lu-PSMA-617

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CabazitaxelDrug

    Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.

  • 177Lu-PSMA-617Drug

    Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.

Study groups in NCT05340374
Study groupRoleWhat they receive
Treatment ArmExperimentalIn this single-arm study, patients will receive 7.4 GBq of 177Lu-PSMA-617 on Day 1 of every 6 week Cycle. Cabazitaxel will be administered concurrently on Day 2 and Day 23 of each Cycle (every 3 weeks). The dose of cabazitaxel will vary in dose-escalation. Up to 6 Cycles will be given.
Receives: Drug: Cabazitaxel; Drug: 177Lu-PSMA-617

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with Dose Limiting Toxicities (DLTs)

    A DLT is defined as a toxicity that prevents further administration of the trial treatment at that dose level.

    Each cohort of 3 patients be assessed for DLTs in the first 6 weeks (cycle 1) of treatment and a dose for the next cohort will be determined.

    Measured: Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited.

  2. Maximum Tolerated dose (MTD)

    The MTD is defined as the highest dose level at which the incidence of DLT was less than 2/6.

    Measured: Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited.

  3. Recommended Phase 2 Dose (RP2D)

    After the MTD is established, additional patients will be treated at the MTD. Safety and efficacy data from the study will be used to define the RP2D.

    Measured: Up to 30 months from the time the first patient is recruited.

Secondary outcomes (9)

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs) measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Safety of the combination will be measured by AEs and SAEs.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  2. 50% Prostate-Specific Antigen Response Rate (PSA-RR)

    PSA will be assessed at baseline and every 3 weeks from cycle 1 day 1. PSA response will be defined as a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  3. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) in patients with measurable disease

    Objective Response (OR) is only applicable for the subset of patients with measurable disease by RECIST1.1. OR is defined as a partial response (PR) or complete response (CR) at any stage from time of commencement of protocol treatment to the time of subsequent systemic anti-cancer treatment. The ORR is calculated as the proportion of patients with a best response of CR or PR.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  4. Radiographic Progression-Free Survival (rPFS)

    rPFS is defined as the time from treatment initiation to the first date of documented radiographic progression using conventional imaging or death due to any cause, whichever occurs first. The radiographic progression will be assessed by the investigator per RECIST1.1 for soft tissue and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) for bone lesions.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  5. PSA progression free survival (PSA-PFS)

    PSA-PFS is defined as the time from treatment initiation to the date of PSA progression per PCWG3 or death due to any cause, whichever occurs first. The date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2ng/mL or more from the nadir is documented. For patients who have an initial PSA decline during treatment, this must be confirmed by a second value 3 or more weeks later.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  6. Overall survival (OS)

    OS is defined as the time from treatment initiation to the date of death due to any cause.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

  7. Describe pain within 12 months of treatment commencement

    Pain will be assessed using the Brief Pain Inventory - Short Form (BPI-SF). This form assesses pain at its "worst," "least," "average," and "now" (current pain) in a 24-hour period at different timepoints, using a scale from 0-10. A higher score indicates more severe pain. The primary endpoint is the area under the curve (AUC) obtained from repeated patient responses to the BPI-SF item concerning "worst pain" in 24 hours.

    Pain will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.

    Measured: Through completion of 12 months after treatment commencement of last patient

  8. Describe health-related quality of life (QoL) within 12 months of treatment commencement

    QoL will be assessed using the Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) questionnaire. The primary endpoint for QoL is the area under the curve (AUC) of the trial outcome index (TOI), which is the sum of the Functional Assessment of Cancer Therapy -General (FACT-G), physical well-being, functional well-being, and prostate cancer subscale (PCS) scores. The score ranges from 0-156. A higher score indicates better quality of life.

    QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.

    Measured: Through completion of 12 months after treatment commencement of last patient

  9. Rate of treatment discontinuation due to toxicity

    The percentage of patients who discontinue treatment due to treatment related toxicity will be reported.

    Measured: Through study completion, up until 24 months after the last patient commences treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2022
  2. Study start14 Jul 2022
  3. Primary completion20 Jun 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05340374
Sponsor's protocol ID
21/018
Acronym
LuCAB
Status last verified
Apr 2025
First submitted
14 Apr 2022
Last updated
6 Apr 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, Crumbaker M, Emmett L, Hofman MS, Azad AA. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025 Apr 1;66(4):572-578. doi: 10.2967/jnumed.124.269252.

    PubMed 39978808

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing Cabazitaxel and 177Lu-PSMA-617 in people with Metastatic Castration-resistant Prostate Cancer and mCRPC, run by Peter MacCallum Cancer Centre, Australia at 2 sites in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 6 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with Dose Limiting Toxicities (DLTs) (time frame: Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05340374, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in